Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
The DOI matches its Crossref record; 75 of the 77 references it cites were found in a registry or an index.
Abstract
Heterozygous mutations in catalytic arginine residues of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) are common in glioma, acute myeloid leukemia, chondrosarcoma, cholangiocarcinoma, and angioimmunoblastic T-cell lymphoma. The mutant enzymes acquire a neomorphic activity that converts α-ketoglutarate (α-KG) to D-2-hydroxyglutarate (D2HG), a rare metabolite. In cells and tissues expressing mutant IDH, D2HG concentrations are highly elevated. D2HG may act as an “oncometabolite” by inhibiting a class of α-KG–dependent enzymes involved in epigenetic regulation, collagen synthesis, and cell signaling. Knock-in mouse models of IDH1 mutations have shed light on these mechanisms and will provide valuable animal models for further investigation. Significance: Mutations in IDH1 and IDH2 promote the development of a number of malignancies. These active site mutations cause a gain-of-function leading to the accumulation of the rare metabolite D2HG. Mouse models of these mutations should provide insights into the mechanisms driving tumorigenesis and facilitate evaluation of new treatments. Cancer Discov; 3(7); 730–41. ©2013 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [7]
In the citing paper
“This can occur through multiple distinct mechanisms, including recurrent gain- or loss-of function mutations in enhancer of zeste 2 (EZH2), the primary methyltransferase responsible for this histone modification 99 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [99]
In the citing paper
“EZH2 catalyses mono-, di- and tri-methylation of H3K27, which is linked to transcriptional silencing 99 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [99]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Cited by
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
Insulator dysfunction and oncogene activation in IDH mutant gliomas
Flavahan, W. A., Drier, Y., Liau, B. B., Gillespie, S. M., Venteicher, A. S., Stemmer-Rachamimov, A. O., Suvà, M. L., & Bernstein, B. E. (2016) · Nature · doi:10.1038/nature16490 · Cited by 1,288
Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies
Rani, V., Deep, G., Singh, R. K., Palle, K., & Yadav, U. C. S. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.02.002 · Cited by 1,139
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
“, 2010) constitute the majority of mutational events and lead to the occurrence of GBM, AML, chondrosarcoma, cholangiocarcinoma, and angioimmunoblastic T-cell lymphoma (Cairns and Mak, 2013; Lu et al., 2013).”
BackgroundEpigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
Okugawa, Y., Grady, W. M., & Goel, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.011 · Cited by 782
A vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 706
Metabolomics in cancer research and emerging applications in clinical oncology
Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Vander Heiden, M. G., & Locasale, J. W. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21670 · Cited by 648
Transcription factors as readers and effectors of DNA methylation
Zhu, H., Wang, G., & Qian, J. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.83 · Cited by 649
Intraoperative brain cancer detection with Raman spectroscopy in humans
Jermyn, M., Mok, K., Mercier, J., Desroches, J., Pichette, J., Saint-Arnaud, K., Bernstein, L., Guiot, M.-C., Petrecca, K., & Leblond, F. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2384 · Cited by 618
“As part of the standard neuropathological analysis, each tumor is also tested for the IDH1 (R132H)mutation, a known glioma marker (42).”
MethodNew Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
N6-methyladenosine links RNA metabolism to cancer progression
Dai, D., Wang, H., Zhu, L., Jin, H., & Wang, X. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0129-x · Cited by 473
DNA methylation: An epigenetic mark of cellular memory
Kim, M., & Costello, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.10 · Cited by 450
Metabolic control of epigenetics in cancer
Kinnaird, A., Zhao, S., Wellen, K. E., & Michelakis, E. D. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.82 · Cited by 420
Oldham, W. M., Clish, C. B., Yang, Y., & Loscalzo, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.021 · Cited by 364
“While D2HG is a so-called ‘‘oncometabolite’’ produced bymutations in IDH associated with an increasing number of human malignancies (Cairns and Mak, 2013), these data reinforce the notion that D2HG and L2HG are separate and distinct metabolites with unique effects on metabolic regulation (Struys,…”
Miquel, S., Leclerc, M., Martin, R., Chain, F., Lenoir, M., Raguideau, S., Hudault, S., Bridonneau, C., Northen, T., Bowen, B., et al. (2015) · mBio · doi:10.1128/mbio.00300-15 · Cited by 318
“Its involvement in cell proliferation and differentiation through the activity of the AKG-acid-dependent enzymes has recently been reviewed (23).”
BackgroundKickingereder, P., Sahm, F., Radbruch, A., Wick, W., Heiland, S., Deimling, A. V., Bendszus, M., & Wiestler, B. (2015) · Scientific Reports · doi:10.1038/srep16238 · Cited by 316
“…genes encoding IDH-1/2 are recurrently mutated in several cancers, which induce a neomorphic enzyme activity that results in the production of the oncometabolite (R)-2HG , unveiled a fascinating and complex biology behind the dysregulation and functional consequences of metabolites in cancers 29 .”
Glioma: experimental models and reality
Lenting, K., Verhaak, R., ter Laan, M., Wesseling, P., & Leenders, W. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1671-4 · Cited by 287
“The biology of IDH mutations has been extensively studied and is covered in excellent reviews e.g. [1, 18].”
Isocitrate dehydrogenase mutations in gliomas
Waitkus, M. S., Diplas, B. H., & Yan, H. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov136 · Cited by 282
An Overview: The Diversified Role of Mitochondria in Cancer Metabolism
Liu, Y., Sun, Y., Guo, Y., Shi, X., Chen, X., Feng, W., Wu, L.-L., Zhang, J., Yu, S., Wang, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81609 · Cited by 247
“Mutations in IDH1 and IDH2 induce epigenetic and transcriptional reprogramming, and differentiation bias and promote the development of a number of malignancies [99, 100] including but not limited to chondrosarcoma, AML [101, 102], cholangiocarcinoma [103], prostate cancers [104], angioimmunoblastic T-cell lymphomas […”
BackgroundCaveolin-1 in the regulation of cell metabolism: a cancer perspective
Nwosu, Z. C., Ebert, M. P., Dooley, S., & Meyer, C. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0558-7 · Cited by 256
Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
Akins, N. S., Nielson, T. C., & Le, H. V. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180523111351 · Cited by 253
Hypoxia/pseudohypoxia‐mediated activation of hypoxia‐inducible factor‐1α in cancer
Hayashi, Y., Yokota, A., Harada, H., & Huang, G. (2019) · Cancer Science · doi:10.1111/cas.13990 · Cited by 216
Roles of RNA methylation by means of N6-methyladenosine (m6A) in human cancers
Wang, S., Sun, C., Li, J., Zhang, E., Ma, Z., Xu, W., Li, H., Qiu, M., Xu, Y., Xia, W., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.030 · Cited by 227
Grady, W. M., Yu, M., & Markowitz, S. D. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.058 · Cited by 214
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer
Clark, O., Yen, K., & Mellinghoff, I. K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1333 · Cited by 206
“These metabolic changes can have a profound effect on the ability of cells to proliferate, differentiate, and escape cell death, and may introduce therapeutic vulnerabilities (56-64).”
BackgroundCytokine-like Roles for Metabolites in Immunity
Zasłona, Z., & O’Neill, L. A. J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.002 · Cited by 199
Wang, P., Wu, J., Ma, S., Zhang, L., Yao, J., Hoadley, K. A., Wilkerson, M. D., Perou, C. M., Guan, K.-L., Ye, D., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.029 · Cited by 206
“(reviewed by Cairns and Mak, 2013; Yang et al., 2012).”
Inoue, S., Li, W. Y., Tseng, A., Beerman, I., Elia, A. J., Bendall, S. C., Lemonnier, F., Kron, K. J., Cescon, D. W., Hao, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.018 · Cited by 195
“…that ATM expression is lower in IDH1mutant formation about the effects of IDH1 mutations in HSCs that may Mutation in isocitrate dehydrogenase-1 (IDH1-R132) confers an enzymatic activity that converts a-ketoglutarate (aKG) to the oncometabolite D-2-hydroxyglutarate (D2HG) (Cairns and Mak, 2013).”
BackgroundInfluentialSelf-citationThe Epigenetic Hallmarks of Cancer
Esteller, M., Dawson, M. A., Kadoch, C., Rassool, F. V., Jones, P. A., & Baylin, S. B. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0296 · Cited by 160
Driver mutations of cancer epigenomes
Roy, D. M., Walsh, L. A., & Chan, T. A. (2014) · Protein & Cell · doi:10.1007/s13238-014-0031-6 · Cited by 186
“The effects of mutant IDH are pleiotropic and affect numerous cell processes including DNA methylation, histone methylation, HIF1a signaling, collagen synthesis, and metabolism (Cairns and Mak, 2013).”
BackgroundAdoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
Wang, Z., & Cao, Y. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00176 · Cited by 184
“There is a statistic showing that more than 70% of diffuse grade II and grade III gliomas carry the most frequent mutation, IDH1R132H (72, 73).”
BackgroundInfluentialMolenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., van Noorden, C. J. F., & Bleeker, F. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.004 · Cited by 182
Molecular targeting of hypoxia in radiotherapy
Rey, S., Schito, L., Koritzinsky, M., & Wouters, B. G. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.10.002 · Cited by 172
Protein oxidation, UVA and human DNA repair
Karran, P., & Brem, R. (2016) · DNA Repair · doi:10.1016/j.dnarep.2016.05.024 · Cited by 164
Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction
Cheng, C.-T., Qi, Y., Wang, Y.-C., Chi, K. K., Chung, Y., Ouyang, C., Chen, Y.-R., Oh, M. E., Sheng, X., Tang, Y., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0178-4 · Cited by 167
Metabolic consequences of oncogenic IDH mutations
Parker, S. J., & Metallo, C. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.003 · Cited by 158
“Most patients who developed metastatic brain tumors exhibited high levels of L-2HG, not D-2HG, and tumors that develop are of a different type than those commonly associated with IDH mutation (Cairns & Mak, 2013).”
BackgroundCaravella, J. A., Lin, J., Diebold, R. B., Campbell, A.-M., Ericsson, A. M., Gustafson, G. R., Wang, Z., Castro, J., Clarke, A., Gotur, D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01423 · Cited by 161
Saha, S. K., Gordan, J. D., Kleinstiver, B. P., Vu, P., Najem, M. S., Yeo, J.-C., Shi, L., Kato, Y., Levin, R. S., Webber, J. T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1442 · Cited by 160
“These mutations occur within the isocitrate binding site of IDH1 (R132) or IDH2 (R172, R140) and cause altered enzymatic function, leading to the production of R (–)-2-hydrox- yglutarate (2-HG), a proposed “oncometabolite” ( 15 ).”
Guerra, F., Guaragnella, N., Arbini, A., Bucci, C., Giannattasio, S., & Moro, L. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00295 · Cited by 167
Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017) · Cancer · doi:10.1002/cncr.31039 · Cited by 169
“ascorbate as cofactors, tying nutrient sensing to the regulation of many cellular processes.(23,24) Perhaps the most notable members of the a-KG-dependent dioxygenases are the ten-eleven translocation (TET) enzyme family of 5”
BackgroundRobey, R. B., Weisz, J., Kuemmerle, N. B., Salzberg, A. C., Berg, A. S., Brown, D. G., Maurer, L. L., Palorini, R., Al‐Mulla, F., Al-Temaimi, R. A., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv037 · Cited by 162
Effects of Exercise on Tumor Physiology and Metabolism
Pedersen, L., Christensen, J. F., & Hojman, P. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000096 · Cited by 134
“Recent advances in cancer metabolism show that mutations in major metabolic pathways (MYCN, IDH, p53, etc) play an instrumental role in tumorigenesis.(49,50) But regulation of the metabolic flow might even in these reprogrammed tumors be responsive to external hormonal signals seen during exercise.”
Backgroundde Botton, S., Fenaux, P., Yee, K. W. L., Récher, C., Wei, A. H., Montesinos, P., Taussig, D. C., Pigneux, A., Braun, T., Curti, A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009411 · Cited by 149
“Thrombocytopenia 30 (20) 25 (16) 8 (5) 6 (4)”
InfluentialBorger, D. R., Goyal, L., Yau, T., Poon, R. T., Ancukiewicz, M., Deshpande, V., Christiani, D. C., Liebman, H. M., Yang, H., Kim, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2649 · Cited by 138
“There have been tremendous advances in our understanding of how mutants IDH1 and IDH2 drive the tumorigenic process (22).”
Bladder Cancer Biomarker Discovery Using Global Metabolomic Profiling of Urine
Wittmann, B. M., Stirdivant, S. M., Mitchell, M. W., Wulff, J. E., McDunn, J. E., Li, Z., Dennis-Barrie, A., Neri, B. P., Milburn, M. V., Lotan, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115870 · Cited by 143
“For example, 2-hydroxyglutarate is increased in gliomas, multiple myeloma and colon cancer [29] and elevated sarcosine is associated with prostate and colorectal cancer [30, 31].”
Extracellular vesicles as a platform for ‘liquid biopsy’ in glioblastoma patients
Santiago-Dieppa, D. R., Steinberg, J., Gonda, D., Cheung, V. J., Carter, B. S., & Chen, C. C. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.943193 · Cited by 127
“The native function of the protein catalyzes the oxidative decarboxylation of isocitrate to a-ketoglutarate [56].”
BackgroundRong, Z., Li, Z., He, J., Liu, L.-Y. D., Ren, X.-X., Gao, J., Mu, Y., Guan, Y., Duan, Y., Zhang, X., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00369 · Cited by 134
Peripheral T cell lymphomas: from the bench to the clinic
Fiore, D., Cappelli, L. V., Broccoli, A., Zinzani, P. L., Chan, W. C., & Inghirami, G. G. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0247-0 · Cited by 138
2-Hydroxyglutarate in Cancer Cells
Ježek, P. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130
Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells
Rasola, A., Neckers, L., & Picard, D. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.03.005 · Cited by 129
Watts, J. M., Baer, M. R., Yang, J., Prébet, T., Lee, S., Schiller, G. J., Dinner, S. N., Pigneux, A., Montesinos, P., Wang, E. S., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00292-7 · Cited by 130
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
Cho, Y. S., Levell, J. R., Liu, G., Caferro, T. R., Sutton, J. C., Shafer, C. M., Costales, A., Manning, J. R., Zhao, Q. L., Sendzik, M., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00342 · Cited by 127
Lemonnier, F., Cairns, R. A., Inoue, S., Li, W. Y., Dupuy, A., Broutin, S., Martin, N., Fataccioli, V., Pelletier, R., Wakeham, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617929114 · Cited by 121
“However, beyond TET2 inhibition, 2HG can inhibit multiple α-KG– dependent dioxygenases involved in various cell functions, including histone methylation, the hypoxia response, and collagen maturation (1) that all could contribute to the oncogenic process.”
BackgroundSelf-citationMetabolomic signature of brain cancer
Pandey, R., Caflisch, L., Lodi, A., Brenner, A. J., & Tiziani, S. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22694 · Cited by 134
Metabolic Regulation of Redox Balance in Cancer
Purohit, V., Simeone, D. M., & Lyssiotis, C. A. (2019) · Cancers · doi:10.3390/cancers11070955 · Cited by 117
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia
Fenouille, N., Bassil, C. F., Ben‐Sahra, I., Benajiba, L., Alexe, G., Ramos, A., Pikman, Y., Conway, A. S., Burgess, M. R., Li, Q., et al. (2017) · Nature Medicine · doi:10.1038/nm.4283 · Cited by 126
Endothelial cell metabolism: parallels and divergences with cancer cell metabolism
Verdegem, D., Moens, S., Stapor, P., & Carmeliet, P. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-19 · Cited by 110
“called 2-hydroxy-glutarate that may participate in tumor progression [107-109].”
BackgroundEpigenetic mechanisms and the hallmarks of cancer: an intimate affair.
Darwiche, N. (2020) · PubMed Central · Cited by 163
Metabostemness: A New Cancer Hallmark
Menéndez, J. A., & Alarcón, T. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00262 · Cited by 119
Yoshimi, N., Futamura, T., Bergen, S. E., Iwayama, Y., Ishima, T., Sellgren, C., Ekman, C. J., Jakobsson, J., Pålsson, E., Kakumoto, K., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.217 · Cited by 109
Metabolism and epigenetics: a link cancer cells exploit
Carrer, A., & Wellen, K. E. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.11.012 · Cited by 109
“inhibits α-ketoglutarate-dependent JMJD histone demethylases and TET methylcytosine dioxygenases, thereby mediating a hypermethylation phenotype (reviewed in[6,11,12]).”
BackgroundItsumi, M., Inoue, S., Elia, A., Murakami, K., Sasaki, M., Lind, E. F., Brenner, D., Harris, I. S., Chio, I. I. C., Afzal, S., et al. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.38 · Cited by 112
“The Idh2 enzyme is a homodimer and is also localized in mitochondria but uses NADP as a coenzyme.(1)”
BackgroundInfluentialSelf-citationSalminen, A., Haapasalo, A., Kauppinen, A., Kaarniranta, K., Soininen, H. S., & Hiltunen, M. O. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.001 · Cited by 113
“In addition, mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and 2) convert isocitrate, a Krebs cycle metabolite, to R( )-2-hydroxyglutarate, instead of 2-oxoglutarate (Xu et al., 2011; Cairns and Mak, 2013).”
BackgroundMolecular profiling of biliary tract cancer: a target rich disease
Jain, A., & Javle, M. M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.01 · Cited by 113
“Subsequently, these were identified in other solid tumors including cholangiocarcinoma (31).”
BackgroundTanboon, J., Williams, E. A., & Louis, D. N. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlv009 · Cited by 103
“D-2-hydroxyglutarate causes epigenetic alterations by blocking histone demethylation, interrupting cellular differentiation (8, 9) but promoting cell proliferation (10).”
BackgroundNatsume, A., Arakawa, Y., Narita, Y., Sugiyama, K., Hata, N., Muragaki, Y., Shinojima, N., Kumabe, T., Saito, R., Motomura, K., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac155 · Cited by 93
Epigenetics in Cancer: A Hematological Perspective
Stahl, M. F., Kohrman, N., Gore, S. D., Kim, T. K., Zeidan, A. M., & Prébet, T. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006193 · Cited by 99
Chen, F., Bian, K., Tang, Q., Fedeles, B. I., Singh, V., Humulock, Z. T., Essigmann, J. M., & Li, D. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00009 · Cited by 94
Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
Zhang, P., & Zhang, M. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00962-x · Cited by 101
Pancreatic tumor cell metabolism: Focus on glycolysis and its connected metabolic pathways
Guillaumond, F., Iovanna, J., & Vasseur, S. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2013.12.019 · Cited by 90
Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity
Goldman, S. L., Hassan, C., Khunte, M., Soldatenko, A., Jong, Y., Afshinnekoo, E., & Mason, C. E. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00133 · Cited by 101
D-2-Hydroxyglutarate in Glioma Biology
Chou, F.-J., Liu, Y., Lang, F., & Yang, C. (2021) · Cells · doi:10.3390/cells10092345 · Cited by 96
“The evidence could provide the perspective that D-2-HG contributes to genomic instability and facilitates malignancy transformation [107].”
BackgroundMitochondrial dysfunction in cancer chemoresistance
Guaragnella, N., Giannattasio, S., & Moro, L. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.027 · Cited by 90
“8 oncometabolite recently identified is 2-hydroxyglutarate, which accumulates following gain-offunction mutations in another enzyme of the TCA cycle, NADP-dependent isocitrate dehydrogenase (IDH) 1 (cytosolic) and 2 (mitochondrial) in different cancer types, including acute myeloid leukemia, glioma, chondrosarcoma and…”
McAdam, E., Brem, R., & Karran, P. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0053 · Cited by 86
“To investigate further the connection between NADPH levels and NER inhibition, we used HT1080 chondrosarcoma cells.”
InfluentialGlioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science
Hochberg, F. H., Atai, N. A., Gonda, D. D., Hughes, M. S., Mawejje, B., Balaj, L., & Carter, R. S. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.905202 · Cited by 95
“Peripheral blood samples have also been analyzed, and a murine model has been studied for clarification of disease mechanism [66,67].”
BackgroundPersistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
Ok, C. Y., Loghavi, S., Sui, D., Wei, P., Kanagal‐Shamanna, R., Yin, C. C., Zuo, Z., Routbort, M. J., Tang, G., Tang, Z., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191148 · Cited by 86
“IDH1 R132 mutation and IDH2 R140/R172 mutations reduce α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate (also known as R2-hydroxyglutarate).(14,15) D-2-hydroxyglutarate has structural similarities to α-ketoglutarate and can competitively inhibit enzymes dependent on α-ketoglutarate, such as the TET enzyme fa…”
BackgroundThe Emerging Role of Epitranscriptomics in Cancer: Focus on Urological Tumors
Lobo, J., Barros‐Silva, D., Henrique, R., & Jerónimo, C. (2018) · Genes · doi:10.3390/genes9110552 · Cited by 91
“Moreover, FTO plays a role in response to all-trans-retinoic acid (ATRA) and, interestingly, D-2-hydroxyglutarate (D2-HG) (the metabolite accumulated in isocitrate dehydrogenase 1 and 2 (IDH1/2)-mutant leukemias (20% of AMLs)) functions as an inhibitor of FTO demethylase, meaning that FTO expression is context-depende…”
BackgroundInfratentorial IDH-mutant astrocytoma is a distinct subtype
Banan, R., Stichel, D., Bleck, A. C., Hong, B., Lehmann, U., Suwala, A. K., Reinhardt, A., Schrimpf, D., Buslei, R., Stadelmann, C., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02194-y · Cited by 91
“Even though all tumor-associated IDH1 and IDH2 mutations result in acquisition of a neo-enzymatic activity with the ability to convert α-ketoglutarate (α-KG) to the oncometabolite 2-hydroxyglutarate (2-HG), the spectrum of IDH mutation subtypes differs widely between different types of cancer [9].”
BackgroundReconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 91
Mitochondrial Flexibility of Breast Cancers: A Growth Advantage and a Therapeutic Opportunity
Avagliano, A., Ruocco, M. R., Aliotta, F., Belviso, I., Accurso, A., Masone, S., Montagnani, S., & Arcucci, A. (2019) · Cells · doi:10.3390/cells8050401 · Cited by 93
Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair
Lamarca, Á., Barriuso, J., McNamara, M. G., & Valle, J. W. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.002 · Cited by 87
Friend or foe—IDH1 mutations in glioma 10 years on
Huang, L. E. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz134 · Cited by 90
“Furthermore, IDH1 and IDH2 mutations are rare or non-existent in cancer types outside of the central nervous system (11,15,16), with the exception of cartilaginous tumors, leukemia and lymphoma, and intrahepatic cholangiocarcinomas (17,18) (Table 2).”
BackgroundJiang, L., Boufersaoui, A., Yang, C., Ko, B., Rakheja, D., Guevara, G., Hu, Z., & DeBerardinis, R. J. (2016) · Metabolic Engineering · doi:10.1016/j.ymben.2016.11.004 · Cited by 87
“It is worth noting that mice with germline deficiency of IDH1 are viable and fertile, suggesting that systemic IDH1 inhibition is tolerated in normal, unstressed tissues (Cairns and Mak, 2013).”
BackgroundBoehme, K. A., Schleicher, S., Traub, F., & Rolauffs, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010311 · Cited by 87
“Indeed, generation of 2-HG not only reduces α-KG abundance but 2-HG directly inhibits enzymes dependent on α-KG by occupying the binding site [172].”
BackgroundInfluentialShigeta, K., Hasegawa, M., Hishiki, T., Naito, Y., Baba, Y., Mikami, S., Matsumoto, K., Mizuno, R., Miyajima, A., Kikuchi, E., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022110620 · Cited by 90
““Reverse” flux from a-KG to citrate has often been observed in several cancers with IDH2 gene mutations, such as low-grade glioma and AML (Cairns & Mak, 2013; Chan et al, 2015).”
BackgroundInfluentialCoussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, G. S., Simeonov, A. M., & Hall, M. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013755 · Cited by 82
“Further research revealed that over 75% of some brain cancers and 20% of AML carry such an IDH1/2 mutation, and the mutations occur in a range of other solid tumors, including chondrosarcoma, cholangiocarcinoma, colorectal, and prostate cancer (Cairns and Mak, 2013).”
BackgroundTET methylcytosine oxidases: new insights from a decade of research
Lio, C.-W. J., Yue, X., López-Moyado, I. F., Tahiliani, M., Aravind, L., & Rao, A. (2020) · Journal of Biosciences · doi:10.1007/s12038-019-9973-4 · Cited by 79
“For example, gainof-function mutations in the isocitrate dehydrogenases, IDH1 and IDH2, lead to accumulation of 2-HG, and mutations in these genes are frequently observed in patients with acute myeloid leukemia (AML) and glioblastoma (Dang et al. 2010; Cairns and Mak 2013; Losman and Kaelin 2013).”
BackgroundEmerging Technologies to Image Tissue Metabolism
Ntziachristos, V., Pleitez, M. A., Aime, S., & Brindle, K. M. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.004 · Cited by 82
A noncoding single-nucleotide polymorphism at 8q24 drives IDH1 -mutant glioma formation
Yanchus, C., Drucker, K. L., Kollmeyer, T. M., Tsai, R., Winick‐Ng, W., Liang, M., Malik, A., Pawling, J., Lorenzo, S. B. D., Ali, A., et al. (2022) · Science · doi:10.1126/science.abj2890 · Cited by 84
Self-citationIDH Mutation, Competitive Inhibition of FTO, and RNA Methylation
Elkashef, S. M., Lin, A.-P., Myers, J., Sill, H., Jiang, D., Dahia, P. L. M., & Aguiar, R. C. T. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.001 · Cited by 78
“In agreement with Li et al. (2017), four of the five AMLs with highest FTO expression in our series were NPM1-mutant and/or had FLT3 internal ll 31, May 8, 2017 ª 2017 Elsevier Inc. 619 tandem duplication, including two cases also harboring IDH1/2 mutations; the described association ofNPM1/IDHmutations in AML adds an…”
BackgroundInfluentialGlioma Cells with the IDH1 Mutation Modulate Metabolic Fractional Flux through Pyruvate Carboxylase
Izquierdo-Garcia, J. L., Cai, L. M., Chaumeil, M. M., Eriksson, P., Robinson, A. E., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108289 · Cited by 75
“It has previously been shown that 2-HG can cause global changes in gene expression by altering the activity of JmjC histone 5-methylcytosine hydroxylases and TET cytosine demethylases, [7].”
BackgroundBartesaghi, S., Graziano, V., Galavotti, S., Henriquez, N. V., Betts, J., Saxena, J., Minieri, V., Deli, A., Karlsson, A., Martins, L. M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413165112 · Cited by 82
“This can occur through inactivation of components of the tricarboxylic acid (TCA) cycle and electron transport chain (ETC) (1-5).”
BackgroundUo, T., Sprenger, C. C. T., & Plymate, S. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580617 · Cited by 88
Modeling epigenetic lesions that cause gliomas
Rahme, G. J., Javed, N. M., Puorro, K. L., Xin, S., Hovestadt, V., Johnstone, S. E., & Bernstein, B. (2023) · Cell · doi:10.1016/j.cell.2023.06.022 · Cited by 79
Emerging circulating biomarkers in glioblastoma: promises and challenges
Touat, M., Durán-Peña, A., Alentorn, A., Lacroix, L., Massard, C., & Idbaïh, A. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1087315 · Cited by 81
“IDH1 and IDH2 encode enzymes that catalyze the oxidation of isocitrate to a-ketoglutarate in the tricarboxylic acid cycle [130].”
BackgroundChen, J.-Y., Lai, Y.-S., Tsai, H.-J., Kuo, C.-C., Yen, B. L., Yeh, S.-P., Sun, H. S., & Hung, W.-C. (2016) · Scientific Reports · doi:10.1038/srep32428 · Cited by 73
Colorectal cancer: epigenetic alterations and their clinical implications
Puccini, A., Berger, M. D., Naseem, M., Tokunaga, R., Battaglin, F., Cao, S., Hanna, D. L., McSkane, M., Soni, S., Zhang, W., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.09.003 · Cited by 86
“IDH-1 and IDH-2 mutations have been identified in rare tumors, such as glioma, but also in chondrosarcoma, cholangiocarcinoma, a small proportion of prostate cancers, and angioimmunoblastic T-cell lymphomas (AITL) (26), while TET mutations are found in leukemias, where they were originally discovered (27).”
Background
Metadata
- Authors
- Cairns, R. A., & Mak, T. W.
- Affiliations
- University Health Network (CA)
- Venue
- Cancer Discovery
- Published
- 2013-07-01
- Volume
- 3
- Issue
- 7
- Pages
- 730-741
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2111163869
- Cited by
- 452
- References
- 77
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 26 · 2023: 26 · 2022: 31 · 2021: 33 · 2020: 45 · 2019: 33 · 2018: 43 · 2017: 46 · 2016: 50 · 2015: 44 · 2014: 37 · 2013: 4
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- IDH mutation, IDH1, IDH2, 2-hydroxyglutarate, oncometabolites, alpha-ketoglutarate, gain-of-function mutations, epigenetic regulation, collagen synthesis, knock-in mice, glioma, acute myeloid leukemia, cholangiocarcinoma, angioimmunoblastic T-cell lymphoma, chondrosarcoma, carcinogenesis
- MeSH terms
- Animals, Arginine, Glutarates, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasms, Gene Expression Regulation, Neoplastic, Epigenesis, Genetic, Mice, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.